INNOCARE PHARMA LTD (33C.F)
Chart Events
Performance Outlook
| Previous Close | 0.9300 |
| Open | 0.9400 |
| Bid | 0.9400 x N/A |
| Ask | 1.0200 x N/A |
| Day's Range | 0.9400 - 0.9400 |
| 52 Week Range | 0.9000 - 1.7700 |
| Volume | |
| Avg. Volume | 25 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
SF Intra-city's revenue surged 25.6% YoY to exceed RMB10 Billion
Hangzhou SF Intra-city Industrial Co., Ltd. ("SF Intra-city" or the "Group"; Stock Code: 9699.HK), the largest third-party on-demand delivery service provider in China, announced its audited annual results for the year ended 31 December 2022 (the "Reporting Period"). During the Reporting Period, the Group adhered to its goal of pursuing long-term sustainable and high-quality growth. The Group demonstrated robust business resilience by steadily expanding its business while continuing to improve i
- Business Wire
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
BEIJING, December 21, 2022--InnoCare Pharma (HKEX: 09969; SSE: 688428) announced today that the Company has received approval from the Center for Drug Evaluation (CDE) to conduct a single-arm, open-label, multi-cohort phase II clinical trial evaluating the efficacy and safety of orelabrutinib in combination with tafasitamab + lenalidomide for the treatment of patients with relapsed or refractory Non-Hodgkin's lymphoma (NHL).
- Business Wire
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
BEIJING, November 22, 2022--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
